Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gautam G Rao & David Scott Miller. (2006) Hormonal therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy 6:1, pages 43-47.
Read now
Read now
A Gadducci, S Cosio, A Gargini & AR Genazzani. (2004) Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecological Endocrinology 19:4, pages 216-228.
Read now
Read now
A. Gadducci & A. R. Genazzani. (1999) Endocrine therapy for gynecological cancer. Gynecological Endocrinology 13:6, pages 441-456.
Read now
Read now
Articles from other publishers (35)
Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers & Jurgen MJ. Piek. (2023) Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. Heliyon, pages e23170.
Crossref
Crossref
Hongyi Li, Yu Liu, Yang Wang, Xia Zhao & Xiaorong Qi. (2021) Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). Oncology Reports 46:4.
Crossref
Crossref
Kate Millington, Katherine Hayes, Sarah Pilcher, Stephanie Roberts, Sara O. Vargas, Amanda French, Jennifer Veneris & Allison O’Neill. (2020) A serous borderline ovarian tumour in a transgender male adolescent. British Journal of Cancer 124:3, pages 567-569.
Crossref
Crossref
Taichi Mizushima & Hiroshi Miyamoto. (2019) The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells 8:2, pages 176.
Crossref
Crossref
Laura Paleari & Andrea DeCensi. (2018) Endocrine therapy in ovarian cancer: where do we stand?. Current Opinion in Obstetrics & Gynecology 30:1, pages 17-22.
Crossref
Crossref
Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo & Andrea DeCensi. (2017) Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. Gynecologic Oncology 146:3, pages 504-513.
Crossref
Crossref
Ioannis A. Voutsadakis. (2016) Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clinical Medicine Insights: Oncology 10, pages CMO.S32813.
Crossref
Crossref
Fiona Simpkins, Arlene Garcia-Soto & Joyce Slingerland. (2013) New insights on the role of hormonal therapy in ovarian cancer. Steroids 78:6, pages 530-537.
Crossref
Crossref
Chris Williams, Iveta Simera & Andrew Bryant. (2010) Tamoxifen for relapse of ovarian cancer. Cochrane Database of Systematic Reviews 2020:11.
Crossref
Crossref
Rajul Kothari, Peter Argenta, Jeffrey Fowler, Jori Carter & William Shimp. (2010) Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature. Archive of Oncology Arhiv za onkologiju 18:1-2, pages 32-35.
Crossref
Crossref
Adelaida García-Velasco, César Mendiola, Alfonso Sánchez-Muñoz, Claudio Ballestín, Ramón Colomer & Hernán Cortés-Funes. (2008) Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clinical and Translational Oncology 10:6, pages 367-371.
Crossref
Crossref
C Pisano, S Greggi, M Falanga, G Laurelli, VR Iaffaioli & S Pignata. (2006) Ovarian cancer in older women. Aging Health 2:3, pages 437-447.
Crossref
Crossref
M.A. BOOKMAN. (2005) Is there still a role for hormonal therapy?. International Journal of Gynecological Cancer 15:s3, pages 291-297.
Crossref
Crossref
Kung-Chong Chao, Peng-Hui Wang, Ming-Shyen Yen, Chi-Ching Chang & Chin-Wen Chi. (2005) Role of Estrogen and Progesterone in the Survival of Ovarian Tumors — A Study of the Human Ovarian Adenocarcinoma Cell Line OC-117-VGH. Journal of the Chinese Medical Association 68:8, pages 360-367.
Crossref
Crossref
Anna C. McDonnel, Edward A. Van Kirk, Dale D. Isaak & William J. Murdoch. (2005) Effects of progesterone on ovarian tumorigenesis in xenografted mice. Cancer Letters 221:1, pages 49-53.
Crossref
Crossref
Gautam G. Rao & David S. Miller. (2005) Clinical applications of hormonal therapy in ovarian cancer. Current Treatment Options in Oncology 6:2, pages 97-102.
Crossref
Crossref
G. Balbi, L. D. Piano, A. Cardone & G. Cirelli. (2004) Second-line therapy of advanced ovarian cancer with GnRH analogs. International Journal of Gynecological Cancer 14:5, pages 799-803.
Crossref
Crossref
C.-H. Chien, C.-H. Chen, C.-Y. G. Lee, T.-C. Chang, R.-J. Chen & S.-N. Chow. (2004) Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. International Journal of Gynecological Cancer 14:3, pages 451-458.
Crossref
Crossref
BARBARA C. VANDERHYDEN, TANYA J. SHAW, KENNETH GARSON & ANGELA M. TONARY. 2004. The Ovary. The Ovary
591
612
.
Peter E. Schwartz. 2004. Gynecologic Cancer. Gynecologic Cancer
491
497
.
Anna C. McDonnel, Edward A. Van Kirk, Dale D. Isaak & William J. Murdoch. (2016) Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells. Experimental Biology and Medicine 228:3, pages 308-314.
Crossref
Crossref
Ligita Paskeviciute, Henrik Roed & Svend A. Engelholm. (2002) No Rules without Exception: Long-Term Complete Remission Observed in a Study Using a LH-RH Agonist in Platinum-Refractory Ovarian Cancer. Gynecologic Oncology 86:3, pages 297-301.
Crossref
Crossref
Jose Luis Perez-Gracia & Eva Marı́a Carrasco. (2002) Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future Research. Gynecologic Oncology 84:2, pages 201-209.
Crossref
Crossref
A.C McDonnel & W.J Murdoch. (2001) High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. The Journal of Steroid Biochemistry and Molecular Biology 78:2, pages 185-191.
Crossref
Crossref
Laura J. Havrilesky, Connette P. McMahon, Edward K. Lobenhofer, Regina Whitaker, Jeffrey R. Marks & Andrew Berchuck. (2016) Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones. Journal of the Society for Gynecologic Investigation 8:2, pages 104-113.
Crossref
Crossref
F Duffaud, M EL van der Burg, M Namer, I Vergote, P B Willemse, W ten Bokkel Huinink, J P Guastalla, M A Nooij, P Kerbrat, M Piccart, S Tumolo, G Favalli, N van der Vange, A J Lacave, J Wils, T AW Splinter, N Einhorn, K J Roozendaal, R Rosso & J B Vermorken. (2001) D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anti-Cancer Drugs 12:2, pages 159-162.
Crossref
Crossref
Chris Williams & Iveta Simera. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ruud E. van Rijswijk & Jan B. Vermorken. (2000) Drug Therapy for Gynaecological Cancer in Older Women. Drugs & Aging 17:1, pages 13-32.
Crossref
Crossref
H. C van Doorn. (2000) Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. Journal of Clinical Pathology 53:3, pages 201-205.
Crossref
Crossref
G. Emons & K.-D. Schulz. 2000. Peptides in Oncology III. Peptides in Oncology III
83
94
.
Jae Hoon Kim, Dong Choon Park, Jin Woo Kim, Yang Kyu Choi, Young Ok Lew, Dae Hoon Kim, Jae Keun Jung, Young Ae Lim & Sung Eun Namkoong. (1999) Antitumor Effect of GnRH Agonist in Epithelial Ovarian Cancer. Gynecologic Oncology 74:2, pages 170-180.
Crossref
Crossref
Curt W Burger, Flora E van Leeuwen, Fedde Scheele & Peter Kenemans. (1999) Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 32:2, pages 69-76.
Crossref
Crossref
Hiroho Ohta, Hideki Sakamoto & Kazuo Satoh. (1998) In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Letters 134:1, pages 111-118.
Crossref
Crossref
Christopher J. Williams. (1998) Tamoxifen in relapsed ovarian cancer: A systematic review. International Journal of Gynecological Cancer 8:2, pages 89-94.
Crossref
Crossref
Jean Marie Debois. (2010) Clear clinical remission of a diffuse metastasized ovarian clear cell carcinoma with third line chemotherapy. Acta Obstetricia et Gynecologica Scandinavica 76:7, pages 709-712.
Crossref
Crossref